- Fee assured
- Awaiting verification
Rachel qualified in Cambridge, and trained in London before taking up her current appointment in the Oxford Centre for Respiratory Medicine in 2009. She completed a successful clinical and translational PhD project at the Royal Brompton and Royal Free Hospitals investigating the role of lung injury in scleroderma-associated lung fibrosis.
Her interests include lung fibrosis, asthma, chronic obstructive airways disease, lung infection, cough, and a broad range of general respiratory and general medical conditions.
Rachel is the lead clinician for the Oxford Interstitial Lung Disease Service, and has successfully bid to become a Pirfenidone prescribing centre, and her unit was recognized as a national specialist centre for interstitial lung disease (ILD) in 2014. Rachel has a national profile in ILD, is a regular speaker at national conferences. She is a current member of the ILD Specialist Advisory Group, advising the British Thoracic Society on national policy, has an advisory role with the British Lung Foundation in forming a Patient Charter.
Rachel’s active research interests include clinical trials in idiopathic pulmonary fibrosis (via the active UKCRC Oxford Respiratory Trials Unit), lung diseases associated with vasculitis, immunosuppressant strategies in lung disease associated with rheumatological problems, and imaging modalities in lung fibrosis.
Areas of interest
Lung disease; Pulmonary disease; Cough; Breathlessness; Respiratory infections; Interstitial lung disease; Asthma; COPD; Bronchiectasis; Lung function tests; Abnormal x-ray investigation
Current NHS consultant posts held
Oxford Centre for Respiratory Medicine, Churchill Hospital, Oxford OX3 7LE
Consultant in Respiratory Medicine.
Oxford Interstitial Lung Disease Service Lead Clinician.
- Clinical trials in idiopathic pulmonary fibrosis, research interest in lung vasculitis, immunosuppressant strategies in rheumatic lung disease, lung biomarkers, and imaging modalities in lung fibrosis.
- Completed a clinical and translational PhD project investigating the role of lung injury in scleroderma-associated lung fibrosis.
- Published one of few multi-centre randomised controlled trials in connective tissue disease-associated pulmonary fibrosis.
Family, travel and gardening
- British Thoracic Society (BTS) Young Investigators Prize 2008
- Americal Thoracic Society (ATS), 'Outstanding science symposium: scientific breakthroughs of the year' 2008
- ATS travel grants 2007, 2008, 2008
- BTS Young Investigator runner up 2006
- Emmanual College, Cambridge University 1991-94: Senior Scholarship, Hooper Prize, Windsor Scholarship, Senior Exhibition
- Efficacy of Tocilizumab for interstital lung disease in an undifferentiated auto-inflammatory disorder partially responsive to Anakinra. Keidel S, Hoyles RK, Wilkinson N. Rheumatology (case report; in press)
- Oxford Textbook of Rheumatology, The Respiratory System. Hoyles RK, Wells AU (book chapter; in press)
- Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis. De Lauretis A, …Hoyles R….Wells AU, Renzoni EA. J Rheumatol. 2013 Apr;40(4):435-46 (original research)
- Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Goh NS, … Hoyles RK, .. AU. Eur Respir J. Eur Respir J. 2011 Jul;38(1):184-90 (original research)
- An Essential Role for Resident Fibroblasts in Experimental Lung Fibrosis Is Defined by Lineage-Specific Deletion of High-Affinity Type II Transforming Growth Factor ß Receptor. Hoyles RK et al. Am J Respir Crit Care Med. 2011 Jan 15;183(2):249-61 (original research)
- Fibroblast-specific perturbation of TGFβ signalling provides insight into potential pathogenic mechanisms of scleroderma associated lung fibrosis: exaggerated response to alveolar epithelial injury in a novel mouse model. RK Hoyles et al. Arthritis Rheum 2008 Mar 27;58(4):1175-1188 (original research)
- Pulmonary Fibrosis In Collagen Vascular Disease. RK Hoyles, AU Wells. Diffuse Parenchymal Lung Disease. Prog Respir Res Basel, Karger 2007, vol 36, pp185-195 (book chapter)
- A multicenter, prospective, randomised, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. RK Hoyles et al. Arthritis Rheum 2006 Nov 28; 54(12):3962-3970 (original research)
- Treatment of Idiopathic Pulmonary Fibrosis: a European Perspective. RK Hoyles, RM du Bois. Clinical Pulmonary Medicine 2006; 13(1):17-24 (review)
Courses offered to GPs
Occasional invited speaker to the Oxfordshire GP seminars held at the Manor Hospital
- FRCP Royal College of Physicians, London 2013
- PhD UCL, London 2009
- CCT Respiratory and General Medicine London 2009
- MRCP Royal College of Physicians, London 2000
- MB BChir Cambridge School of Clinical Medicine 1996
- MA Hons (Cantab) Emmanuel College, Cambridge 1994
Reference number 4368412
Professional bodies (positions held - last 3 yrs)
- Specialist Advisory Group for Interstitial Lung Disease British Thoracic Society 2012
Details of entry to specialist register
- CCT in Respiratory and General Internal Medicine, 2009
Affiliations / memberships
•British Thoracic Society (BTS)
•Interstitial Lung Disease ILD Specialist Advisory Group BTS
•Royal College of Physicians
•British Medical Association
•Oxford Deanery Specialist Training Committee
- Nuffield Health The Manor Hospital, OX3 7RP
- 15:30 - 17:30
- 01865 307728
- Oxford Centre for Respiratory Medicine,...
- 12:00 - 14:00
- 01865 225223
Post treatment communication
Following treatment of a Bupa member, I will communicate with GPs in line with Department of Health, GMC and appropriate professional bodies guidelines.
In the event of an urgent query following treatment, Bupa members should use the following contact details
Dr Rachel Hoyles via secretary Amanda Williams (Manor) 01865 307728